Cyclin G2 promotes cell cycle arrest in breast cancer cells responding to fulvestrant and metformin and correlates with patient survival

Metformin attenuates transforming growth factor beta (TGF-β) mediated oncogenesis in mesenchymal stem-like/claudin-low triple negative breast cancer

(2016) Reema Wahdan-Alaswad et al.   CELL CYCLE

Repurposing old drugs to chemoprevention: the case of metformin

(2016) Brandy M. Heckman-Stoddard et al.   SEMINARS IN ONCOLOGY

The changing role of ER in endocrine resistance

(2015) Agostina Nardone et al.   BREAST

Highly specific role of the insulin receptor in breast cancer progression

(2015) R. Rostoker et al.   ENDOCRINE-RELATED CANCER

Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study

(2015) Matthew J. Ellis et al.   JOURNAL OF CLINICAL ONCOLOGY

Enhancing Endocrine Therapy for Hormone Receptor–Positive Advanced Breast Cancer: Cotargeting Signaling Pathways

(2015) Stephen R. D. Johnston   JNCI-Journal of the National Cancer Institute

The BMI1 polycomb protein represses cyclin G2-induced autophagy to support proliferation in chronic myeloid leukemia cells

(2015) L Mourgues et al.   LEUKEMIA

The influence of insulin-like Growth Factor-1-Receptor expression and endocrine treatment on clinical outcome of postmenopausal hormone receptor positive breast cancer patients: A Dutch TEAM substudy analysis

(2015) Charla C. Engels et al.   Molecular Oncology

Clinical management of breast cancer heterogeneity

(2015) Dimitrios Zardavas et al.   Nature Reviews Clinical Oncology

Challenges in the management of advanced, ER-positive, HER2-negative breast cancer

(2015) Christopher D. Hart et al.   Nature Reviews Clinical Oncology

Obesity and cancer, a case for insulin signaling

(2015) Y Poloz et al.   Cell Death & Disease

Enhancing Endocrine Therapy for Hormone Receptor–Positive Advanced Breast Cancer: Cotargeting Signaling Pathways

(2015) Stephen R. D. Johnston   JNCI-Journal of the National Cancer Institute

Ligand-Binding Affinity at the Insulin Receptor Isoform-A and Subsequent IR-A Tyrosine Phosphorylation Kinetics are Important Determinants of Mitogenic Biological Outcomes

(2015) Harinda Rajapaksha et al.   Frontiers in Endocrinology

Metformin and erlotinib synergize to inhibit basal breast cancer

(2015) Ying-Ka Ingar Lau et al.   Oncotarget

Metformin enhances tamoxifen-mediated tumor growth inhibition in ER-positive breast carcinoma

(2014) Ji Ma et al.   BMC CANCER

The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer

(2014) Eva Ciruelos et al.   BREAST

Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions

(2014) Agnieszka K Witkiewicz et al.   BREAST CANCER RESEARCH

Overview of cyclins D1 function in cancer and the CDK inhibitor landscape: past and present

(2014) Mathew C Casimiro et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Metformin—mode of action and clinical implications for diabetes and cancer

(2014) Ida Pernicova et al.   Nature Reviews Endocrinology

Obesity and cancer—mechanisms underlying tumour progression and recurrence

(2014) Jiyoung Park et al.   Nature Reviews Endocrinology

Reprogramming ovarian and breast cancer cells into non-cancerous cells by low-dose metformin or SN-38 through FOXO3 activation

(2014) Theodore Hu et al.   Scientific Reports

Down-regulation of cyclin G2 by insulin, IGF-I (insulin-like growth factor 1) and X10 (AspB10 insulin): role in mitogenesis

(2013) Angela M. Svendsen et al.   BIOCHEMICAL JOURNAL

Understanding response and resistance to oestrogen deprivation in ER-positive breast cancer

(2013) N. Patani et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

D-type Cyclins are important downstream effectors of cytokine signaling that regulate the proliferation of normal and neoplastic mammary epithelial cells

(2013) Qian Zhang et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer

(2013) Balázs Győrffy et al.   PLoS One

CDK10/cyclin M is a protein kinase that controls ETS2 degradation and is deficient in STAR syndrome

(2013) V. J. Guen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A Kinome-Wide Screen Identifies the Insulin/IGF-I Receptor Pathway as a Mechanism of Escape from Hormone Dependence in Breast Cancer

(2011) E. M. Fox et al.   CANCER RESEARCH

The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells

(2011) Alejandro Vazquez-Martin et al.   CELL CYCLE

Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer

(2011) C. A. Lange et al.   ENDOCRINE-RELATED CANCER

Insulin receptor and cancer

(2011) A. Belfiore et al.   ENDOCRINE-RELATED CANCER

A novel function of the proneural factor Ascl1 in progenitor proliferation identified by genome-wide characterization of its targets

(2011) D. S. Castro et al.   GENES & DEVELOPMENT

Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast Cancer

(2011) Todd W. Miller et al.   JOURNAL OF CLINICAL ONCOLOGY

Nodal enhances the activity of FoxO3a and its synergistic interaction with Smads to regulate cyclin G2 transcription in ovarian cancer cells

(2011) G Fu et al.   ONCOGENE

Proyl isomerase Pin1 facilitates ubiquitin-mediated degradation of cyclin-dependent kinase 10 to induce tamoxifen resistance in breast cancer cells

(2011) P Khanal et al.   ONCOGENE

GOBO: Gene Expression-Based Outcome for Breast Cancer Online

(2011) Markus Ringnér et al.   PLoS One

Neural stem and progenitor cells shorten S-phase on commitment to neuron production

(2011) Yoko Arai et al.   Nature Communications

The Insulin Receptor: A New Target for Cancer Therapy

(2011) Roberta Malaguarnera et al.   Frontiers in Endocrinology

Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells

(2010) Mahvash Zakikhani et al.   BREAST CANCER RESEARCH AND TREATMENT

Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifen-resistant, and estrogen-deprived MCF-7 cells

(2010) Lev M. Berstein et al.   BREAST CANCER RESEARCH AND TREATMENT

Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects

(2010) G M Marshall et al.   ONCOGENE

Insulin Receptor Isoforms and Insulin Receptor/Insulin-Like Growth Factor Receptor Hybrids in Physiology and Disease

(2009) Antonino Belfiore et al.   ENDOCRINE REVIEWS

Differential Signaling Activation by Insulin and Insulin-Like Growth Factors I and II upon Binding to Insulin Receptor Isoform A

(2009) Antonella Sacco et al.   ENDOCRINOLOGY

mTOR supports long-term self-renewal and suppresses mesoderm and endoderm activities of human embryonic stem cells

(2009) J. Zhou et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Identification of CDK10 as an Important Determinant of Resistance to Endocrine Therapy for Breast Cancer

(2008) Elizabeth Iorns et al.   CANCER CELL

Cotylenin A, a new differentiation inducer, and rapamycin cooperatively inhibit growth of cancer cells through induction of cyclin G2

(2008) Takashi Kasukabe et al.   CANCER SCIENCE

Transcriptional regulation of the cyclin D1 gene at a glance

(2008) E. A. Klein et al.   JOURNAL OF CELL SCIENCE

Cyclin G2 Is Degraded through the Ubiquitin-Proteasome Pathway and Mediates the Antiproliferative Effect of Activin Receptor-like Kinase 7

(2008) Guoxiong Xu et al.   MOLECULAR BIOLOGY OF THE CELL